U.S.-GCC DUAL-HUB INNOVATION ENGINE

Translating Sovereign Science into Platform-Grade Biotechnologies.

GenRey connects discovery biology, micro-fluidic bioengineering, computational omics, and sovereign deployment infrastructure to turn laboratory breakthroughs into population-scale clinical platforms.

01 / R&D Core
6 Vectors
Discovery Biology
02 / Intelligence
DAMI™ AI
Omics Modeling
03 / Market TAM
$20B+ Market
Near-Term Commercial
TRANSLATIONAL ARCHITECTURE

A Dual-Hub Engine Bridging Discovery & Sovereign Scale

GenRey rejects the slow, traditional single-asset model. Our dual-hub architecture pairs American biotechnology translation with sovereign-scale regional deployment across the Middle East and beyond.

DISCOVERY & PROTOTYPING TEXAS, USA HUB

U.S. Innovation & Translation Engine

Anchored in Texas, this engine brings together elite physician-scientists, PhD biophysicists, and micro-fluidic engineers to drive foundational research, bioactive synthesis, and device prototyping.

  • Over 25 active R&D candidate programs under discovery
  • Micro-fluidic kinetic delivery device prototyping
  • Rigorous U.S. preclinical validation & IP filings
Core Output Validated IP & Clinical Formulations
SOVEREIGN DEPLOYMENT GCC & GLOBAL HUB

Partner Deployment & Sovereign Infrastructure

Connecting American scientific innovation directly with sovereign strategic partners across the Kingdom of Saudi Arabia, the UAE, and Qatar to establish localized manufacturing and population-scale clinical delivery.

  • Sovereign bio-manufacturing facility establishment
  • Regional clinical trial acceleration & hospital integration
  • IP co-ownership & workforce capability building
Core Output Sovereign Biotech Capability & Clinical Access
Active Pipeline Background
ACTIVE SCIENTIFIC PIPELINE

Six Core R&D Vector Fields

Select a vector below to explore how GenRey combines device engineering, biological synthesis, and computational intelligence.

FLAGSHIP COMMERCIAL PLATFORM

Hair Regeneration & Scalp Bio-Rejuvenation

iREY™ Multimodal Handheld Platform

iREY™ combines a proprietary micro-fluidic delivery device with a high-potency bioactive serum ecosystem. Engineered to reverse follicle cellular senescence, optimize local microcirculation, and re-establish active growth signaling pathways.

$20B+
Global Target TAM
Phase II/III
Trial Sequencing
Key Technical Highlights
  • Micro-droplet kinetic delivery with zero epidermal damage
  • Proprietary bioactive serum preserving protein stability
  • Targeted follicle androgen pathway modulation
  • Designed for rapid clinical & sovereign deployment
R&D Vector Showcase
HARDWARE & BIOACTIVE ECOSYSTEM

iREY™ Delivery Architecture & DAMI™ Intelligence Layer

GenRey bridges the gap between active molecular biological discovery and physical clinical application through integrated hardware micro-fluidics and machine learning omics.

iREY Delivery Device Breakdown
Click numbers on diagram to view component specifications
PATENTED HARDWARE

Micro-Fluidic Kinetic Chamber

Ejects bioactive serum micro-droplets at precise kinetic velocities to bypass outer stratum corneum without thermal or mechanical skin disruption.

DAMI™ Computational Link

The DAMI™ AI platform constantly analyzes kinetic delivery data and tissue uptake telemetry, automatically tuning formulation viscosity and micro-fluidic pulse rates for maximum therapeutic efficacy.

DISCIPLINED EXECUTION ROADMAP

From Bench to Sovereign Clinical Deployment

Every GenRey initiative follows a sequenced 3-stage translational lifecycle designed to mitigate biological risk while optimizing speed to market.

01
PHASE I STAGE

Discovery & IP Creation

Target identification, candidate synthesis, micro-fluidic hardware design, and comprehensive patent portfolio protection.

Key Output: Preclinical Proof-of-Concept & U.S. Patent Filings
02
PHASE II STAGE

Clinical Validation & Trials

Multi-center human clinical trials, dosage optimization, delivery device refinement, and safety protocol standardization.

Key Output: Clinical Safety & Efficacy Dataset
03
PHASE III STAGE

Sovereign Production & Distribution

Establishing regional bio-manufacturing plants, workforce technology transfer, and commercial health system integration.

Key Output: Commercial Sovereign Infrastructure
IP Portfolio Platform Background
IP PORTFOLIO

Proprietary Intellectual Property & Co-Ownership

GenRey builds defensible, high-moat intellectual property across hardware, bioactive formulations, computational models, and sovereign transfer frameworks.

⚙️

Micro-Fluidic Hardware

Patented kinetic micro-droplet chambers, delivery nozzle geometry, and closed-loop sterile cartridge mechanisms.

🧪

Bioactive Serum Formulations

Proprietary peptide complexes, growth factor stabilization matrices, and localized tissue retention compounds.

🧬

DAMI™ AI Biomarker Models

Multi-omics computational pipelines for rapid target discovery and patient-specific dosage optimization.

🏛️

Sovereign Tech Transfer

Structured co-ownership frameworks granting regional partners domestic manufacturing rights and sovereign IP equity.

SCIENTIFIC GOVERNANCE

World-Class Clinical & Scientific Governance

GenRey's R&D engine is guided by leading physician-scientists, micro-fluidic hardware pioneers, and global healthcare system advisors.

Dr. Aaron Wolfson

Dr. Aaron Wolfson

Healthcare & Device Innovation

Specializes in healthcare innovation, medical device integration, and micro-fluidic hardware delivery mechanisms for therapeutic protocols.

View Full Profile →
Dr. Asim Elahi

Dr. Asim Elahi

Clinical Scaling & Integration

Bridges scientific discovery initiatives with healthcare system integration, clinical protocol design, and sovereign deployment.

View Full Profile →
Dr. Jerry Lorren Dominic

Dr. Jerry Lorren Dominic

Therapeutic Protocol Oversight

Advises on clinical trial design, therapeutic safety monitoring, and translational regulatory compliance across international markets.

View Full Profile →
Partner CTA Background
PARTNER WITH GENREY

Accelerate Sovereign Biotechnology in Your Region

We collaborate with sovereign wealth funds, ministry bodies, institutional healthcare providers, and research centers to deploy platform-grade biotech capabilities.